Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[225Ac]-FPI-1966 in FGFR3+ Solid Tumors
NCT05363605Phase 2Terminated
- Sponsor
- Fusion Pharmaceuticals Inc.
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 2, open-label trial of vofatamab + actinium-225 in solid tumor (advanced stage), bladder carcinoma and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Fusion Pharmaceuticals Inc. Primary endpoints: Incidence of Adverse Events at 2 years, Maximum Tolerated Dose at 42 days and 3 more. Started Apr 2022; status: terminated.
02
Drugs
vofatamab + actinium-225
03
Conditions
solid tumor (advanced stage)bladder carcinomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05363605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363605.